*Type of the Paper (Original Research, Review, Editorial, etc.)*

**Title of the Manuscript**

Firstname Lastname1, Firstname Lastname2, Firstname Lastname1,\*

1Department, Institution, ZIP code City, State (if any), Country

2Department, Institution, City, State (Abbreviated format) ZIP code, Country

\*Correspondence: E-mail address (Firstname Lastname)

†These authors contributed equally.

Availability of Data and Materials

For *JIN*, it is strongly encouraged that all datasets on which the conclusions of a manuscript depend should be available to readers, unless they are already provided as part of the submitted article. Where datasets are included in the study, authors should include an “Availability of Data and Materials” section in the article, stating where the data supporting their findings may be found. Authors who do not wish to share their data must state this fact, and also provide an explanation as to why the data are unavailable. More information at: <https://www.imrpress.com/resources/editorial_policies#3._availability_of_data_and_materials>.

Author Contributions

These should be presented as follows: Initials (Author A) and Initials (Author C) designed the research study. Initials (Author B) performed the research. Initials (Author D) provided help and advice on ... Initials (Author A) analyzed the data. Initials (Author B, C and D) wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

This section is required for all papers. Manuscripts reporting studies involving human participants, human data or human tissue must: include a statement on ethics approval and consent (even where the need for approval was waived) include the name of the ethics committee that approved the study and the committee’s reference number if appropriate. Studies involving animals must include a statement on ethics approval. If the article does not involve this part, please add: “Not applicable.” Information about editorial policies at <https://www.imrpress.com/resources/editorial_policies>.

Acknowledgment

This section is required for all papers. Here you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments). Please do not thank the editors in this section, but you can send an email to express thanks.

Funding

This section is required for all papers. Please add: “This research received no external funding.” or “This research was funded by Name of Funder, grant number XXX.”

Conflict of Interest

This section is required for all papers. If there are no interests to declare, please add: “The authors declare no conflict of interest.”

Title of the Manuscript

Abstract

The abstract must include the following separate sections: **Background**: The context and purpose of the study; **Methods**: How the study was performed and statistical tests used; **Results**: Succinct presentation of key results; please include sample sizes throughout; **Conclusions**: Brief summary and potential implications; **Clinical Trial registration**: When applicable, include a fifth heading, “Clinical Trial Registration.” Please include the Unique Identifier and the URL of the publicly accessible website on which the trial is registered. If the data have been deposited in a public repository and/or are being used in a secondary analysis, authors should state at the end of the abstract the unique, persistent data set identifier; repository name; and number.

Keywords

keyword 1; keyword 2; keyword 3; keyword 4 [List at least three but no more than ten pertinent keywords.]

# 1. Introduction [first level heading]

State the objectives of the work and provide an adequate background to clarify why the study was undertaken and what hypotheses were tested, avoiding a detailed literature survey or a summary of the results. The information in this section should always be referenced. Also, use the [numbers] for the references in the full text, e.g., [1] or [5, 6, 7] or [9–11].

# 2. Materials and Methods

The source of material used and relevant ethical framework for all experiments should be clearly identified (ethics approval and/or written informed consent). Methods already published should be indicated by a reference: only relevant modifications should be described. This implies that a full description of all the experiments described in Results and presented in the Figures/Tables is expected in this section. For each experiment, all steps need to be mentioned, along with instruments the analyses were performed on, reagents and methods to permit the replication of the work by others. We would encourage authors to submitting a detailed Bio-protocol.

# 3. Results

Include a concise summary of the data presented in all display items (figures and tables). Excessive elaboration of data shown in display items should be avoided. Numerical data should be analyzed using appropriate statistical tests described in the Experimental Design and Statistical Analysis section. Authors must provide detailed information for each statistical test applied. Report exact p values rather than ranges (e.g., *p* = 0.048 rather than *p* < 0.05).

*3.1 Figures, Tables, Motions, and Equations, etc.* [second level heading]

All figures and tables should be cited in the main text as Fig. 1, Table 1, Eqn. 1, Motion 1, etc.

### 3.1.1 Figures [third level heading]

Provide figure images in JPG, TIF format; Color images must be in RGB mode (do not support CMKY mode). The suggested minimum resolution of image is 300 dpi. Figures should be placed in the main text near to the first time they are cited. Also, the legend should be detailed, it is not acceptable to give only one or two lines description of figures.



Fig. 1. Figure title. (A) Description of what is contained in the first subfigure. (B) Description of what is contained in the second subfigure.

### 3.1.2 Tables

Tables should be placed in the main text near to the first time they are cited.

Table 1. This is sample table caption.

|  |  |  |  |
| --- | --- | --- | --- |
| Title 1 | Title 2 | Title 3 | Title 4 |
| Entry 1 | data | data | data |
| Entry 2 | data | data | data |
| Entry 3 | data | data | data |
| Entry 4 | data | data | data |

Table footnotes.

### 3.1.3 Mathematical Components

This is the example 1 of equation [fourth level heading]

$a = 1$ (1)

the text following an equation need not be a new paragraph. Please punctuate equations as regular text.

This is the example 2 of equation

$a = b + c + d + e + x + y = X.$ (2)

The text following an equation if were a new paragraph, please punctuate equations as regular text.

*3.2 Units*

* A space should be inserted before measurement units: 17 mL, 17 mol/L, 17 cm.
* Capitalize the letter L in some units: mL, L.
* The letter p should be lowercase and in italic type: *p*, *p*-value.
* Decimal points should use a full stop (.) NOT a comma (,): 0.17, 10.375.

# 4. Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

# 5. Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section. However, if the article type is Original Research, there must be a Conclusions section, which should be distinguished from the Discussion section.

Abbreviations [optional section]

AAA, abdominal aortic aneurysm; AVF, arteriovenous fistula; IVC, inferior vena cava; CRRT, continuous renal replacement therapy; CT, computed tomography; ICU, intensive care unit; ALT, alanine transaminase; AST, aspartate transaminase; TBIL, total bilirubin; DBIL, direct bilirubin.

Supplementary Material [optional section]

Authors of accepted manuscripts may provide related supplemental data to be posted online along with the published manuscript. All Supplemental Data information (except videos) should be combined into a single Word/PDF file. Before submission, carefully review all files; if you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. The journal is not responsible for any errors contained in data supplements.

Appendix [optional section]

All appendix materials must be cited in the main text.

References and Notes

[1] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Article title. Title of journal. Year; volume: pages.

[2] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Article title. Title of journal. Year; volume: pages. (In Language)

[3] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Book Title. Edition - if available. Publisher: City, Country. Year.

[4] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Title of chapter. In Surname of the editor(s) Initial(s) (ed(s).) Book title Page. Edition. Publisher: City, Country. Year.

[5] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Title. Year. Available at: URL (Accessed: Day month year).

[6] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. ‘Title of paper’, Title of the conference. Place and date of the conference. Publisher: City, Country. Year of Publication.

[7] The advantage of endnotes, is that they are all arranged sequentially in one place, regardless of the length of individual notes.